What should you know about monoclonal antibodies targeted therapy?

A monoclonal antibody is designed to bind to one particular marker on a cell or in the tissue around it. Binding may block a growth signal, mark a cell for immune attack, or carry another treatment close to cells with the matching marker. The exact action depends on the medicine and the cancer being treated.

The relevant marker may be checked on tumour tissue, blood, or another sample. A positive test does not automatically make one medicine suitable; the team also considers the cancer’s location, previous treatment, organ function, allergies, and other medicines. Some antibodies are used alone, while others are combined with chemotherapy or another treatment.

Tell the oncology team about allergies, autoimmune conditions, heart or lung problems, infections, pregnancy, breastfeeding, and every medicine or supplement you take. Ask whether you need blood tests before each dose. During an infusion, report itching, flushing, chills, back pain, dizziness, chest tightness, or breathlessness immediately so the team can assess the reaction.

Seek urgent help for severe breathing difficulty, swelling of the lips or throat, fainting, chest pain, confusion, a severe rash, persistent fever, or rapidly worsening symptoms after treatment. Contact the team for new diarrhoea, unusual fatigue, yellowing of the skin, reduced urine, or symptoms that continue after an infusion.

Which marker does this antibody recognise, and how was it tested? Is the medicine an infusion or an injection? What reactions can happen during or after treatment? Which symptoms need emergency help? How will heart, lung, liver, kidney, or immune effects be monitored?